Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING (Tables)

v3.21.1
SEGMENT REPORTING (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table is a comparative summary of the Company’s net sales and segment profit by reportable segment for the periods presented:
Three months ended
  March 31,
2021
March 31,
2020
Segment Net Sales:
Cannabinoid $ 677  $ 242 
Non-Cannabinoid 2,800  2,672 
Total Net Sales 3,477  2,914 
 
Segment Profit (Loss):
Cannabinoid (2,864) (5,401)
Non-Cannabinoid 612  480 
Total Segment Loss $ (2,252) $ (4,921)
 
Reconciliation:
Total Segment Loss (2,252) (4,921)
Unallocated corporate expenses (3,387) (1,804)
Non-cash share based compensation (1,550) (416)
Depreciation and amortization (579) (352)
Goodwill impairment   (1,682)
Loss from operations $ (7,768) $ (9,174)
 
Loss on fair value of derivative instrument   13 
Loss(gain) on remeasurement of warrant liability 4,851  — 
Loss on investments   161 
Foreign exchange loss 759  48 
Interest expense 978  836 
Miscellaneous, net (602) (57)
Loss from operations before income taxes $ (13,754) $ (10,175)
March 31,
2021
December 31,
2020
Long-lived assets
   
Cannabinoid $ 27,148  $ 25,485 
Non-Cannabinoid
162  176 
Other(a)
26  19 
  $ 27,336  $ 25,680 
(a)“Other” includes long-lived assets primarily in the Company’s corporate offices.
Disaggregation of Revenue by Channel
The following table disaggregates the Company’s revenues by channel for the for the periods presented:
  Three months ended
  March 31,
2021
March 31,
2020
Mass retail $ 1,888  $ 1,021 
Specialty, health and other retail 225  312 
Distributors 1,232  1,339 
E-commerce 132  242 
$ 3,477  $ 2,914